

1. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? *J Natl Cancer Inst* 2010;102:464–474.
2. Green S, Benedetti J, Crowley J. *Clinical Trials in Oncology*. 2nd ed. London: Chapman & Hall/CRC; 2003.
3. Leventhal BC, Wittes RE. *Research Methods in Clinical Oncology*. New York: Raven Press; 1988.
4. Eisenhauer EA, O'Dwyer PJ, Christian M, et al. Phase I clinical trial design in cancer drug development. *J Clin Oncol* 2000;18:684–692.
5. Simon R, Freidlin B, Rubinstein L. Accelerated titration designs for phase I clinical trials in oncology. *J Natl Cancer Inst* 1997;89:1138–1147.
6. Dancy J, Freidlin B, Rubinstein LV. Accelerated titration designs. In: Chevret S, ed. *Statistical Methods in Dose-Finding Experiments*. New York: Wiley; 2006:91–114.
7. Heath EI, LaRusso PM, Ivy SP, et al. Theoretical and practical application of traditional and accelerated titration phase I clinical trial designs: the Wayne State Experience. *J Biopharm Stat* 2009;19:414–423.
8. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for Phase I clinical trials. *Biometrics* 1990;46:33–48.
9. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. *Stat Med* 1998;17:1103–1120.
10. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. *Stat Med* 1995;14:1149–1161.
11. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. *Stat Med* 1995;14:911–922.
12. Simon RM, Steinberg SM, Hamilton M, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. *J Clin Oncol* 2001;19:1848–1854.
13. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. *Oncologist* 2002;7:401–409.
14. Korn EL, Rubinstein LV, Hunsberger SA, et al. Clinical trial designs for cytostatic agents and agents directed at novel molecular targets. In: Adei AA, Buolamwini JK, eds. *Strategies for Discovery and Clinical Testing of Novel Anticancer Agents*. Amsterdam: Elsevier; 2004;366–380.
15. Kummer S, Kinders R, Rubinstein L, et al. Compressing drug development timelines in oncology using phase '0' trials. *Nat Rev Cancer* 2007;7:131–139.
16. Rubinstein LV, Steinberg SM, Kummer S, et al. The statistics of phase 0 trials. *Stat Med* 2010;29:1072–1076.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008;359:1757–1765.
18. Amado RC, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:1626–1634.
19. VanCutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared to best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol* 2007;25:1658–1664.
20. Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. *Clin Cancer Res* 2007;13:6080–6086.
21. LeBlanc M, Rankin C, Crowley J. Multiple Histology Phase II Trials. *Clin Cancer Res* 2009;15:4256–4262.
22. Dobbin KK, Zhao Y, Simon RM. How large a training set is needed to develop a classifier for microarray data? *Clin Cancer Res* 2008;14:108–114.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–247.
24. Simon R. Optimal two-stage designs for phase II clinical trials. *Control Clin Trials* 1989;10:1–10.
25. Ensign L, Gehan EA, Kamer D, et al. An optimal three-stage design for phase II clinical trials. *Stat Med* 1994;13:1727–1736.
26. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. *Biometrics* 1995;51:1372–1383.
27. Conaway M, Petroni G. Designs for phase II trials allowing for a trade-off between response and toxicity. *Biometrics* 1996;52:1375–1386.
28. Dent S, Zee B, Dancy J, et al. Application of a new multinomial phase II stopping rule using response and early progression. *J Clin Oncol* 2001;19:785–791.
29. Seymour L, Ivy SP, Sargent D, et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the National Cancer Institute investigational drug steering committee. *Clin Cancer Res* 2010;16:1764–1769.
30. Vidaurte T, Wilkerson J, Simon R, et al. Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development. *Cancer J* 2009;15:366–373.
31. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. *J Clin Oncol* 2008;26:1346–1354.
32. Korn EL, Freidlin B. Conditional power calculations for clinical trials with historical controls. *Stat Med* 2006;25:2922–2931.
33. Thall PF, Simon R, Estey E. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. *J Clin Oncol* 1996;14:296–303.
34. Estey EH, Thall PF. New designs for phase 2 clinical trials. *Blood* 2003;102:442–448.
35. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. *J Clin Oncol* 2008;26:527–534.
36. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for nontoxic anticancer agents for which time to disease progression is the primary endpoint. *Control Clin Trials* 2000;21:343–359.
37. Seymour L. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. *Curr Pharm Des* 2002;8:2279–2284.
38. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? *J Clin Oncol* 2001;19:265–272.
39. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase 2 trials and a proposal for phase 2 screening trials. *J Clin Oncol* 2005;23:7199–7206.
40. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. *Cancer Treat Rep* 1985;69:1375–1381.
41. Liu PY, Dahlberg S, Crowley J. Selection designs for pilot studies based on survival. *Biometrics* 1993;49:391–398.
42. Liu PY, LeBlanc M, Manisha D. False positive rates of randomized phase II designs. *Control Clin Trials* 1999;20:342–352.
43. Steinberg SM, Venzon DJ. Early selection in a randomized phase II clinical trial. *Stat Med* 2002;21:1711–1726.
44. Logan BR. Optimal two-stage randomized phase II clinical trials. *Clin Trials* 2005;2:5–12.
45. Rosner G, Stadler W, Ratain M. Randomized discontinuation design: application to cytostatic antineoplastic agents. *J Clin Oncol* 2002;20:4478–4484.
46. Freidlin B, Simon R. An evaluation of the randomized discontinuation design. *J Clin Oncol* 2005;23:1–5.
47. Hunsberger S, Zhao Y, Simon R. A comparison of phase II study strategies. *Clin Cancer Res* 2009;15:5950–5955.
48. Goldman B, LeBlanc M, Crowley J. Interim futility analysis with intermediate endpoints. *Clin Trials* 2008;5:14–22.
49. Thall PF. A review of phase 2-3 clinical trial designs. *Lifetime Data Anal* 2008;14:37–53.
50. Sher HI, Heller G. Picking the winners in a sea of plenty. *Clin Cancer Res* 2002;8:400–404.
51. Schaid DJ, Wieand S, Therasse TM. Optimal two-stage screening designs for survival comparisons. *Biometrics* 1990;77:507–513.
52. Thall PF, Simon R, Ellenberg SS. Two-stage selection and testing designs for comparative clinical trials. *Biometrika* 1988;75:303–310.
53. Parmar MK, Barthel FM, Sydes M, et al. Speeding up the evaluation of new agents in cancer. *J Natl Cancer Inst* 2008;100:1204–1214.
54. Freidlin B, Korn EL, Gray R, et al. Multi-arm clinical trials of new agents: some design considerations. *Clin Cancer Res* 2008;14:4368–4371.
55. Freidlin B, McShane LM, Polley MY. Randomized phase II trial designs with biomarkers. *J Clin Oncol* 2012;30:3304–3309.
56. Simon R. Randomized clinical trials. Principles and obstacles. *Cancer* 1994;74:2614–2619.
57. Torri V, Simon R, Russek-Cohen E, et al. Relationship of response and survival in advanced ovarian cancer patients treated with chemotherapy. *J Natl Cancer Inst* 1992;84:407–414.
58. Buyse M, Molensberghs G, Burzykowski T, et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. *Biostatistics* 2000;1:49–67.
59. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. *Stat Med* 1997;16:1965–1982.
60. Korn EL, Albert PS, McShane LM. Assessing surrogates as trial endpoints using mixed models. *Stat Med* 2004;24:163–182.
61. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. *J Clin Oncol* 2009;27:2874–2880.
62. Freidlin B, Korn EL, Hunsberger S, et al. Proposal for the use of progression-free survival in unblinded randomized trials. *J Clin Oncol* 2007;25:2122–2126.
63. Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? *J Clin Oncol* 2008;26:3791–3796.
64. Simon R. An agenda for clinical trials: clinical trials in the genomic era. *Clin Trials* 2004;1:468–470.
65. Simon R. A roadmap for developing and validating therapeutically relevant genomic classifiers. *J Clin Oncol* 2005;23:7332–7341.
66. Simon R. New challenges for 21st century clinical trials. *Clin Trials* 2007;4:167–169.
67. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. *Clin Cancer Res* 2005;10:6759–6763.
68. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Erratum. *Clin Cancer Res* 2006;12:3229.

69. Hoering A, LeBlanc M, Crowley J. Randomized phase III clinical trial designs for targeted agents. *Clin Cancer Res* 2008;14:4358–4367.
70. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. *J Clin Oncol* 2009;27:4027–4034.
71. Simon R. Using genomics in clinical trial design. *Clin Cancer Res* 2008;14:5984–5993.
72. Simon RM. *Genomic Clinical Trials and Predictive Medicine*. Cambridge, UK: Cambridge University Press; 2013.
73. Karuri SW, Simon R. A two-stage Bayesian design for co-development of new drugs and companion diagnostics. *Stat Med* 2012;31:901–914.
74. Freidlin B, Sun Z, Gray R, et al. Phase III clinical trials that integrate treatment and biomarker evaluation. *J Clin Oncol* 2013;31:3158–3161.
75. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. *J Natl Cancer Inst* 2010;102:152–160.
76. Jiang W, Freidlin B, Simon R. Biomarker adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. *J Natl Cancer Inst* 2007;99:1036–1043.
77. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. *Clin Cancer Res* 2005;11:7872–7878.
78. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design for predictive analysis of clinical trials. *Clin Cancer Res* 2010;16:691–698.
79. Hong F, Simon R. Run-in phase III trial designs with pharmacodynamic predictive biomarkers. *J Natl Cancer Inst* 2013;105:1628–1633.
80. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. *J Natl Cancer Inst* 2009;101:1–7.
81. Pocock S, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. *Biometrics* 1975;31:103–115.
82. Kalish LA, Begg CB. Treatment allocation methods in clinical trials: a review. *Stat Med* 1985;4:129–144.
83. Simon R, Simon N. Using randomization tests to preserve type I error with response-adaptive and covariate-adaptive randomization. *Stat Probab Lett* 2011;81:767–772.
84. Rubinstein L, Gail M, Santner T. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. *J Chronic Dis* 1981;34:469–479.
85. Friedman JA, Chalmers TC, Smith HJ. The importance of beta, the type II error, and sample size in the design and interpretation of the randomized control trial: survey of 71 “negative” trials. *The New England Journal of Medicine* 1978;299:690–694.
86. Brittain E, Wittes J. Factorial designs in clinical trials: the effects of non-compliance and subadditivity. *Biometrics* 1989;8:161–171.
87. Simon R, Freedman LS. Bayesian design and analysis of 2 by 2 factorial clinical trials. *Biometrics* 1997;53:456–464.
88. Simon R. Confidence intervals for reporting results from clinical trials. *Ann Intern Med* 1986;105:429–435.
89. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. *Cancer Treat Rep* 1978;62:1037–1040.
90. Durrleman S, Simon R. Planning and monitoring of equivalence studies. *Biometrics* 1990;46:329–336.
91. Simon R. Bayesian design and analysis of active control clinical trials. *Biometrics* 1999;55:484–487.
92. Spiegelhalter DJ, Freedman LS, Parmar MK. Bayesian approaches to randomized trials. *J R Stat Soc Series A General* 1994;157:357–387.
93. Simon R. Bayesian subset analysis: application to studying treatment-by-gender interactions. *Stat Med* 2002;21:2909–2916.
94. Rubin DB. Bayesian inference for causal effects: the role of randomization. *Ann Stat* 1978;6:34–58.
95. Simon R. Discovering the truth about tamoxifen: problems of multiplicity in the evaluation of biomedical data. *J Natl Cancer Inst* 1995;87:627–629.
96. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. *Br J Cancer* 1977;35:1–39.
97. Barr J, Tannock I. Analyzing the same data two ways: a demonstration model illustrate the reporting and misreporting of clinical trials. *J Clin Oncol* 1989;7:969–978.
98. Tannock I, Murphy K. Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results. *J Clin Oncol* 1983;1:66–70.
99. Randomised trial of IV streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. (Second International Study of Infarct Survival) Collaborative Group. *Lancet* 1988;2:349–360.
100. Fleming TR, Green SJ, Harrington DP. Considerations of monitoring and evaluation treatment effects in clinical trials. *Control Clin Trials* 1984;5:55–66.
101. Ellenberg S, Fleming TR, DeMets D. *Data Monitoring Committees in Clinical Trials: A Practical Perspective*. Hoboken, NJ: Wiley; 2002.
102. Smith M, Ungerleider R, Korn E, et al. The role of independent data monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. *J Clin Oncol* 1997;15:2736–2743.
103. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. *J Radiol* 1971;44:793–797.
104. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. *Biometrics* 1979;35:549–556.
105. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. *Control Clin Trials* 1984;5:348–361.
106. Korn EL, Freidlin B, Mooney M. Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. *J Clin Oncol* 2009;27:1712–1721.
107. Freidlin B, Korn EL. Monitoring for lack of benefit: a critical component of a randomized clinical trial. *J Clin Oncol* 2009;27:629–633.
108. DeMets DL. Futility approaches to interim monitoring by data monitoring committees. *Clin Trials* 2006;3:522–529.
109. Lan KKG, Simon R, Halperin M. Stochastically curtailed test in long-term clinical trials. *Commun Stat Sequen Anal* 1982;1:207–219.
110. Berkson J, Gage RP. Calculation of survival rates for cancer. *Proc Staff Meet Mayo Clin* 1950;25:270–286.
111. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. *J Chronic Dis* 1958;8:699–712.
112. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958;53:457–481.
113. Marubini E, Valsecchi MG. *Analysing Survival Data from Clinical Trials and Observational Studies*. New York, NY: Wiley; 1995.
114. Tannock IF. False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons. *J Natl Cancer Inst* 1996;88:206–207.
115. Fleming TR, Watelet L. Approaches to monitoring clinical trials. *J Natl Cancer Inst* 1989;81:188–193.
116. Dixon DO, Simon R. Bayesian subset analysis. *Biometrics* 1991;47:871–881.
117. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. *Biometrics* 1985;41:361–372.
118. Begg CB. Quality of clinical trials. *Ann Oncol* 1990;1:319–320.
119. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials: a survey of three medical journals. *N Engl J Med* 1987;317:426–432.
120. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. *Biometrika* 1977;64:191–199.
121. Simon R, Wittes R. Methodologic guidelines for reports of clinical trials. *Cancer Treat Rep* 1985;69:1–3.
122. Simon R. Randomized clinical trials and research strategy. *Cancer Treat Rep* 1982;66:1083–1087.
123. Simon R. Commentary on “Clinical trials and sample size considerations: Another perspective.” *Stat Sci* 2000;15:95–110.
124. Ioannidis JP. Why most published research findings are false. *PLOS Med* 2005;2:696–701.
125. Begg CB, Berlin JA. Publication bias and dissemination of clinical research. *J Natl Cancer Inst* 1989;81:107–115.
126. Collins R, Gray R, Godwin J, et al. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. *Stat Med* 1987;6:245–254.